Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

BACKGROUND: Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β(2−)agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single doses of navafenterol were investigated in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Balaguer, Victor, Astbury, Carol, Wählby-Hamrén, Ulrika, Jimenez, Eulalia, Seoane, Beatriz, Villarroel, Cristina, Lei, Alejhandra, Aggarwal, Ajay, Psallidas, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487995/
https://www.ncbi.nlm.nih.gov/pubmed/32907566
http://dx.doi.org/10.1186/s12931-020-01347-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487995/
https://www.ncbi.nlm.nih.gov/pubmed/32907566
http://dx.doi.org/10.1186/s12931-020-01347-7

Ejemplares similares